Role of Neuropilin-1 and its expression in Egyptian Acute Myeloid and Acute Lymphoid Leukemia patients

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 169-173

  Younan, Sarah ^a   Elhoseiny, Shereen ^b   Hammam, Amira ^b   Gawdat, Rania ^b   El wakil, Mohamed ^b   Fawzy, Mohamed ^c  

^a Cairo University   (Egypt)

^b Birmingham Children's Hospital   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

ALL; AML; NRP 1

Indexed keywords

NEUROPILIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLAST CELL; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EGYPT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA REMISSION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUROPILIN-1; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84855195077     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.017     Document Type: Article

References (35)

1. Vales A., Kondo R., Aichberger K.J., et al. Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007, 48(10):1997-2007.
2. Zhou J., Mauerer K., Farina L., Gribben J.G. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Bosky 2005, 10:1581-1596.
3. Chen H., Treweeke A.T., West D.C., et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphatic leukemia cells. Blood 2000, 96:3181-3187.
4. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
5. Sulpice E., Plouet J., Berge M., Allanic D., Tobelem G., Rainon T.M. NRP-1 and NRP-2 act as coreceptors, potentiating proangiogenic activity. Blood 2008, 111(4):2036-2045.
6. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
7. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
8. Whitaker G.B., Limberg B.J., Rosenbaum J.S. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF and VEGF(121). J Biol Chem 2001, 276:25520-25531.
9. Miao H.Q., Lee P., Lin H., Soker S., Klgsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000, 14:2532-2539.
10. Zhang B., Gogo I., Fenton R.G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002, 99(6):1885-1893.
11. Matsushita A., Gotzq T., Korc M. Hepatocyte growth factor-mediated cell in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res 2007, 67:10309-10316.
12. Hu B., Guo P., Bar-Joseph I., et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007, 26:5577-5586.
13. Zhang S., Zhau H., Osunkoya A.O., Iqbal S., Xiaojian Y., Fan S., et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010, 9(9):9-24.
14. Guttmann-Raviv N., Kessler O., Shraga-Heled N., Lange T., Herzog Y., Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 2006, 231(1):1-11.
15. Karjalainen K., Jaalouk D.E., Bueso-Ramos C.E., Zurita A.J., Kuniyasu A., Eckhardt B.L., et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 2011, 117(3):920-927.
16. Pan Q., Chanthery Y., Liang W.C., Stawicki S., Mak J., Rathore N., et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11(1):53-67.
17. Padró T., Ruiz S., Bieker R., Bürger H., Steins M., Kienast J., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95(8):2637-2644.
18. Yamada Y., Oike Y., Ogawa H., Ito Y., Fujisawa H., Suda T., et al. Neuropilin-1 on hematopoietic cells as a source of vascular development. Blood 2003, 101(5):1801-1809.
19. Geretti E., Klagsbrun M. Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr 2007, 1(2):56-61.
20. Kawakami T., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Abe Y., et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer (Phila) 2002, 95:2196-2201.
21. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997, 150:815-821.
22. Fiedler W., Graeven U., Ergün S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89:1870-1875.
23. Lu L., Zhang L., Xiao Z.J., et al. Expression and effect of neuropilin-1 in acute myeloid leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007, 15(6):1150-1155.
24. Lu L., Zhang L., Xiao Z.J., Lu S.H., Yang R.C., Han Z.C. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma 2008, 49(2):331-338.
25. Schuch G., Machluf M., Bartsch G., et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin 1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002, 100(13):4622-4628.
26. Murphy P., Ahmed N., Hassan H.T. Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera. Leuk Res 2002, 26:1007-1010.
27. Zhang B., Lewis S.M. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. Eur J Haematol 1989, 43:63-66.
28. Ghannadan M., Wimazal F., Simonitsch I., Sperr W.R., Mayerhofer M., Sillaber C., et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Am J Clin Pathol 2003, 119:663-671.
29. Fiedler W., Graeven U., Ergun S., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997, 11:1234-1237.
30. Padró T., Bieker R., Ruiz S., et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGVR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002, 16:1302-1310.
31. Bellamy W.T., Richter L., Sirjani D., et al. Vascular endothelial growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
32. Konopleva M., Tabe Y., Zeng Z., Andreef M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Res Updates 2009, 12(4-5):103-113.
33. Katoh O., Takahashi T., Oguri T., et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL-1 acting as an antiapoptotic factor. Cancer Res 1998, 58:5565-5569.
34. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
35. Kreuter M., Woelke K., Bieker R., et al. Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 2006, 20(11):1950-1954.